Opinion: Why a controversial decision won’t stop me from serving on FDA advisory committees
Last week’s controversial decision by the FDA to give aducanumab, Biogen’s Alzheimer’s drug, accelerated approval turned the spotlight on the role of FDA advisory committees.
News reports highlighted how the committee that advised the FDA on this drug, of which I was a member, voted against approving it. Since the decision, three members of the committee have resigned from it, one of whom recently called for “a new organization to review drug approvals.”
